Immunotherapies for Cancer Are Focus of Newly Formed Consortium

NEW CANAAN, CT—Treatment options for a variety of cancers are expanding to include an array of exciting new approaches. Along with well-established companies, newer biotechnology and biopharmaceutical firms are looking to break into an emerging market that would provide vaccines for both solid cancers—such as melanoma, prostate, breast, lung, cervical, colon, brain, and ovarian—and blood borne cancers—such as lymphoma, leukemia, and myeloma.

Sabin

Sabin Vaccine Institute to Honor Pharmaceutical Executive, CHF Founders and University President at New York City Benefit Dinner

NEW CANAAN, CT—The Sabin Vaccine Institute presents its highest non-science awards on May 14 to four illustrious groundbreakers in business, social service, and academia. One is the leader of one of the world’s premier pharmaceutical companies, two are collaborators in starting an organization to benefit the nation’s medically underserved children, and a fourth is a prominent university president.

gwu.edu

Accelerating Cancer Vaccine Development is Rallying Cry at 2003 Colloquium on Cancer Vaccines and Immunotherapy

NEW CANAAN, CT— Cancer vaccines present an elusive goal, yet one that is increasingly within reach for biomedical researchers. Their hope is to offer physicians and cancer patients more and better therapy options than radiation and chemotherapy.

Sabin

Sabin Vaccine Institute Taps Ciro A. de Quadros, MD, MPH for International Programs Post

NEW CANAAN, CT—The Sabin Vaccine Institute has named disease eradication champion Ciro A. de Quadros, MD, MPH to lead its international programs. Dr. de Quadros is a distinguished international public health diplomat, having this year completed an eight-year term as director of the Division of Vaccines and Immunization for the Pan American Health Organization (PAHO). Dr.

Sabin

Pages